Free Trial
NASDAQ:AFIB

Acutus Medical (AFIB) Stock Price, News & Analysis

Acutus Medical logo
$0.0020 -0.01 (-80.00%)
As of 12:31 PM Eastern

About Acutus Medical Stock (NASDAQ:AFIB)

Key Stats

Today's Range
$0.0001
$0.0020
50-Day Range
$0.00
$0.05
52-Week Range
$0.00
$0.22
Volume
13,597 shs
Average Volume
36,154 shs
Market Capitalization
$59,558.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.

Receive AFIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acutus Medical and its competitors with MarketBeat's FREE daily newsletter.

AFIB Stock News Headlines

Dalio heeds Buffett’s warning… [$319 million stake in gold]
Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profitable miners selling at deep discounts. I call this price gap the Golden Anomaly — and I’ve put together a full report on my top four picks.
Acutus Medical Announces Operational Downsizing
Acutus Medical Reports Q3 2024 Financial Results
See More Headlines

AFIB Stock Analysis - Frequently Asked Questions

Acutus Medical's stock was trading at $0.0550 on January 1st, 2025. Since then, AFIB stock has decreased by 96.4% and is now trading at $0.0020.
View the best growth stocks for 2025 here
.

Acutus Medical, Inc. (NASDAQ:AFIB) announced its quarterly earnings data on Thursday, November, 11th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by $0.02. The firm had revenue of $4.60 million for the quarter, compared to analysts' expectations of $6.02 million. Acutus Medical had a negative trailing twelve-month return on equity of 311.64% and a negative net margin of 272.74%.

Acutus Medical subsidiaries include Acutus Medical N.V..

Acutus Medical (AFIB) raised $126 million in an IPO on Thursday, August 6th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, BofA Securities and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Shares of AFIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acutus Medical investors own include Enterprise Products Partners (EPD), NVIDIA (NVDA), Arista Networks (ANET), Meta Platforms (META), Nextera Energy Partners (NEP), PayPal (PYPL) and Rio Tinto Group (RIO).

Company Calendar

Last Earnings
11/11/2021
Today
6/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:AFIB
Employees
340
Year Founded
2011

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$81.66 million
Net Margins
-272.74%
Pretax Margin
-30.32%

Debt

Sales & Book Value

Annual Sales
$7.16 million
Price / Cash Flow
N/A
Book Value
($0.03) per share
Price / Book
-0.02

Miscellaneous

Free Float
28,228,000
Market Cap
$14,889.50
Optionable
Optionable
Beta
-0.09

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:AFIB) was last updated on 6/2/2025 by MarketBeat.com Staff
From Our Partners